Trial Profile

A Multiple Dose, Placebo-Controlled Trial to Determine the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of ALD403, a Humanized Anti-(Calcitonin Gene-Related Peptide) Monoclonal Antibody in Healthy Volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 02 Oct 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 Sep 2016 According to an Alder Biopharmaceuticals media release, results from this trial presented at the 5th European Headache and Migraine Trust International Congress (EHMTIC 2016).
15 Sep 2016 Results published in an Alder Biopharmaceuticals Media Release
08 Sep 2016 According to an Alder Biopharmaceuticals media release, results from this trial will be presented at the 5th European Headache and Migraine Trust International Congress (EHMTIC 2016).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com